PRAMEF28P

Across TCGA pan-cancer cohorts, PRAMEF28P RNA is linked to patient survival in 10 of 34 cancer types, making it the most broadly survival-associated PRAMEF28P data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher PRAMEF28P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRAMEF28P expression acts as an unfavorable survival marker.

STAD, BRCA, and LUAD are the cancer types where PRAMEF28P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Tertile	All	0.388	0.671	<.001	81	view →
BRCA	OS	Tertile	II,III,IV	0.136	0.567	.004	42	view →
LUAD	OS	Tertile	III,IV	0.228	0.677	.015	36	view →
CESC	OS	Tertile	IV	0.091	0.593	<.001	36	view →
PCPG	OS	Tertile	All	0.524	0.975	<.001	36	view →
GBM	OS	Tertile	All	0.117	0.435	<.001	18	view →
UCEC	OS	Tertile	IV	0.231	0.592	.036	18	view →
LGG	DFS	Tertile	All	0.678	0.834	.021	9	view →
BLCA	OS	Tertile	III,IV	0.173	0.579	.038	9	view →
KIRP	OS	Tertile	All	0.250	0.711	.007	9	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

PRAMEF28P–STAD (DFS)

Open the STAD breakdown →